References
- BokhmanJV. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol 1983;15:10–17.
- SamarnthaiN, HallK, YehIT. Molecular profiling of endometrial malignancies. Obstet Gynecol Int 2010;2010:162363.
- ShermanME. Theories of endometrial carcinogenesis: a multidisciplinary approach. Mod Pathol 2000;13:295–308.
- CatalanoS, GiordanoC, RizzaP, GuG, BaroneI, BonofiglioD, GiordanoF, MalivindiR, GaccioneD, LanzinoM, De AmicisF, AndòS. Evidence that leptin through STAT and CREB signaling enhances cyclin D1 expression and promotes human endometrial cancer proliferation. J Cell Physiol 2009;218:490–500.
- ChenCL, HsiehFC, LiebleinJC, BrownJ, ChanC, WallaceJA, ChengG, HallBM, LinJ. Stat3 activation in human endometrial and cervical cancers. Br J Cancer 2007;96:591–599.
- PallaresJ, Martínez-GuitarteJL, DolcetX, LlobetD, RueM, PalaciosJ, PratJ, Matias-GuiuX. Survivin expression in endometrial carcinoma: a tissue microarray study with correlation with PTEN and STAT-3. Int J Gynecol Pathol 2005;24:247–253.
- BinaiNA, DamertA, CarraG, SteckelbroeckS, LöwerJ, LöwerR, WesslerS. Expression of estrogen receptor alpha increases leptin-induced STAT3 activity in breast cancer cells. Int J Cancer 2010;127:55–66.
- YuanR, KayA, BergWJ, LebwohlD. Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapy. J Hematol Oncol 2009;2:45.
- PecorelliS. Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int J Gynaecol Obstet 2009;105:103–104.
- WincewiczA, KodaM, SulkowskaM, Kanczuga-KodaL, SulkowskiS. Comparison of STAT3 with HIF-1α, Ob and ObR expressions in human endometrioid adenocarcinomas. Tissue Cell 2008;40:405–410.
- AtkinsonGP, NozellSE, BenvenisteET. NF-κB and STAT3 signaling in glioma: targets for future therapies. Expert Rev Neurother 2010;10:575–586.
- YoonYK, KimHP, HanSW, Oh doY, ImSA, BangYJ, KimTY. KRAS mutant lung cancer cells are differentially responsive to MEK inhibitor due to AKT or STAT3 activation: implication for combinatorial approach. Mol Carcinog 2010;49:353–362.
- HoJN, KangGY, LeeSS, KimJ, BaeIH, HwangSG, UmHD. Bcl-X(L) and STAT3 mediate malignant actions of γ-irradiation in lung cancer cells. Cancer Sci 2010 Mar 4. [Epub ahead of print].
- HuangS, SinicropeFA. Sorafenib inhibits STAT3 activation to enhance TRAIL-mediated apoptosis in human pancreatic cancer cells. Mol Cancer Ther 2010;9:742–750.
- EscudierB, EisenT, StadlerWM, SzczylikC, OudardS, SiebelsM, NegrierS, ChevreauC, SolskaE, DesaiAA, RollandF, DemkowT, HutsonTE, GoreM, FreemanS, SchwartzB, ShanM, SimantovR, BukowskiRM (TARGET Study Group). Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356:125–134.
- GigliaJL, AntoniaSJ, BerkLB, BrunoS, DessureaultS, FinkelsteinSE. Systemic therapy for advanced hepatocellular carcinoma: past, present, and future. Cancer Control 2010;17:120–129.
- ZagouriF, BozasG, KafantariE, TsiatasM, NikitasN, DimopoulosMA, PapadimitriouCA. Endometrial cancer: what is new in adjuvant and molecularly targeted therapy? Obstet Gynecol Int 2010;2010:749579.
- LlobetD, EritjaN, YeramianA, PallaresJ, SorollaA, DomingoM, SantacanaM, Gonzalez-TalladaFJ, Matias-GuiuX, DolcetX. The multikinase inhibitor Sorafenib induces apoptosis and sensitises endometrial cancer cells to TRAIL by different mechanisms. Eur J Cancer 2010;46:836–850.
- TrovatoM, GrossoM, VitarelliE, RuggeriRM, AlesciS, TrimarchiF, BarresiG, BenvengaS. Distinctive expression of STAT3 in papillary thyroid carcinomas and a subset of follicular adenomas. Histol Histopathol 2003;18:393–399.
- TrovatoM, D'ArmientoM, LavraL, UlivieriA, DominiciR, VitarelliE, GrossoM, VecchioneR, BarresiG, SciacchitanoS. Expression of p53/HGF/c-met/STAT3 signal in fetuses with neural tube defects. Virchows Arch 2007;450:203–210.